[Schistosomiasis mansoni infection in a hyperendemic region of midwestern Madagascar: epidemiology, morbidity and secondary effects of praziquantel treatment].
The examination of 544 inhabitants (93.2% of the whole population) of a village in the middle west of Madagascar, where Schistosoma mansoni is hyperendemic and where no previous antischistosomal treatment had been delivered at a community level, showed a prevalence rate of 61.8%. The highest prevalences and the most intense infections were observed in the 10-24 age group. The egg count decreases dramatically from the age of 25. A highly significant relationship was found between recent histories of bloody diarrhoea and S. mansoni eggs excretion. Clinical examination showed a high frequency of splenomegalies (62.2% > or = stade 2 Hackett), with two modes: one in the 10-14 age group and the other in the 35-39 age group. The respective liability of S. mansoni and malaria remain to be clarified. Side effects after treatment of the entire population with praziquantel were observed in 27.2% of treated individuals. Side effects occurred mainly in infected people. A highly significant relationship was found between intensity of infection and frequency of these side effects which are essentially mild and disappear in the 24 hours.
Boisier
P
P
Institut Pasteur de Madagascar.
Ravaoalimalala
V A
VA
Serieye
J
J
Roux
J
J
Esterre
P
P
D000293:Adolescent; D000328:Adult; D017677:Age Distribution; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008270:Madagascar / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009017:Morbidity; D011159:Population Surveillance; D011223:Praziquantel / Q000009:adverse effects*; D015995:Prevalence; D012555:Schistosomiasis mansoni / Q000188:drug therapy* / Q000453:epidemiology* / Q000469:parasitology; D017678:Sex Distribution
D011223:Praziquantel
Infection a Schistosoma mansoni dans un foyer d'hyperendemie du moyen ouest de Madagascar: épidémiologie, morbidité et effets secondaires liés au traitement par praziquantel.